The therapeutic effect of SAMiRNA-AREG, reported in mouse models and characterized by the stable silencing of the AREG gene, resulting in a reduction in the side effects of conventional siRNA treatment of pulmonary fibrosis, has also been evaluated in renal fibrosis [50]. Here, AREG is linked to renal fibrosis.